As Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted the lid on yet another trial failure involving two drugs aimed at this
It’s not far off crunch time for Roche’s potential spinal muscular atrophy (SMA) drug, risdiplam, which the big Swiss pharma hopes will generate blockbuster revenues as well as taking marke
A state-run research institute in China has applied for a patent on the use of Gilead’s experimental antiviral drug remdesivir, which has been suggested as a potential treatment for the cor
The Netherlands’ biotech sector has already seen an upswing following the relocation of the European Medicines Agency (EMA) to Amsterdam following Brexit, according to an influential figure
